Lemelson Capital Releases Investment Report On Ligand Pharmaceuticals (NASDAQ: LGND)

MARLBOROUGH, Mass., June 16, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today released a 25 page research report on Ligand Pharmaceuticals (NASDAQ: LGND).

The full research report on Ligand can be found here.

Disclosure:  Lemelson Capital is currently short shares of LGND for its clients.

About Lemelson Capital Management

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments.  The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds.  For more information, see: http://www.lemelsoncapital.com

For further information, please contact:

+ Emmanuel Lemelson 
Chief Investment Officer 
Lemelson Capital Management, LLC 
Telephone: 508-630-2281

SOURCE Lemelson Capital Management, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED